Table 2 Per-patient results for target genes of Sorafenib, Lenvatinib, Cabozantinib, and Ramucirumab. ([43,44,45,46])
Gene | Down-regulated DEPC | Up-regulated DEPC | Down-regulated in all-patients analysis | Up-regulated in all-patients analysis | Targeted by |
|---|---|---|---|---|---|
VEGFR2/KDR | 15 | 11 | No | No | Sorafenib, Lenvatinib, Ramucirumab, Cabozantinib |
VEGFR1/FLT1 | 7 | 22 | No | No | Sorafenib, Lenvatinib, Cabozantinib |
VEGFR3/FLT4 | 14 | 3 | No | No | Sorafenib, Lenvatinib, Cabozantinib |
FLT3 | 11 | 5 | Yes | No | Sorafenib |
PDGFRA | 37 | 0 | Yes | No | Lenvatinib |
PDGFRB | 3 | 21 | No | No | Sorafenib |
FGFR1 | 31 | 2 | Yes | No | Lenvatinib |
FGFR2 | 34 | 7 | Yes | No | Lenvatinib |
FGFR3 | 20 | 6 | No | No | Lenvatinib |
FGFR4 | 4 | 14 | No | No | Lenvatinib |
KIT | 1 | 9 | No | No | Sorafenib, Lenvatinib |
RET | 28 | 2 | Yes | No | Sorafenib, Lenvatinib, Cabozantinib |
AXL | 32 | 0 | Yes | No | Cabozantinib |
MET | 3 | 10 | No | No | Cabozantinib |
BRAF | 1 | 5 | No | No | Sorafenib |
RAF1 | 1 | 1 | No | No | Sorafenib |